‘Amazing’ trial shows drug combination stops lung cancer advancing for longer
Patients diagnosed with advanced forms of lung cancer who took the combination of amivantamab and lazertinib were still alive with no progression in their disease after 23.7 months on average.
A global phase 3 study found that combining the monoclonal antibody amivantamab with the tyrosine‑kinase inhibitor lazertinib prolonged progression‑free survival by an average of 23.7 months in patients with advanced EGFR‑mutated non‑small‑cell lung cancer, compared with 16.6 months with the standard drug osimertinib.
The combination offers a substantially longer period of disease control than the existing standard of care for EGFR‑mutated NSCLC, potentially improving patients’ quality of life and survival prospects.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT